Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 1 Cancer Trials

New Haven, Connecticut

Phase 1 cancer trials in New Haven, CT

73 Phase 1 cancer studies are recruiting participants at sites in New Haven as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 927-9038
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

New Haven at a glance

Breast cancer studies recruiting in New Haven

Basic details from each study's public record (the 30 most recently updated of 73). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    Yale University School of Medicine
    Registry record
    NCT06324357 · updated
  2. Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    EMD Serono Research & Development Institute, Inc.
    Study site
    Yale University - Yale University School of Medicine
    Registry record
    NCT07360314 · updated
  3. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Stemline Therapeutics, Inc.
    Study site
    Yale Comprehensive Cancer Center
    Registry record
    NCT06638307 · updated
  4. An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    BeOne Medicines
    Study site
    Yale Cancer Center
    Registry record
    NCT07222267 · updated
  5. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    Yale Cancer Center
    Registry record
    NCT07503808 · updated
  6. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    ORIC Pharmaceuticals
    Study site
    Yale Cancer Center
    Registry record
    NCT05315700 · updated
  7. A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    NiKang Therapeutics, Inc.
    Study site
    Yale Cancer Center
    Registry record
    NCT07029399 · updated
  8. A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer

    • Phase 1
    • Ages 18 and older
    • Female participants
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Yale University School Of Medicine
    Registry record
    NCT07524855 · updated
  9. A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Immunome, Inc.
    Study site
    Yale Cancer Center
    Registry record
    NCT07578571 · updated
  10. Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Yale New Haven Hospital
    Registry record
    NCT07604571 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in New Haven, CT on ClinicalTrials.gov.

Lung cancer studies recruiting in New Haven

  1. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Institut de Recherches Internationales Servier
    Study site
    Yale University School of Medicine - Yale Cancer Center
    Registry record
    NCT05786924 · updated
  2. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Yale University
    Registry record
    NCT06287775 · updated
  3. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    Yale University
    Registry record
    NCT07111520 · updated
  4. Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    SystImmune Inc.
    Study site
    Yale Cancer Center
    Registry record
    NCT07080242 · updated
  5. A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Yale Cancer Center
    Registry record
    NCT05789082 · updated
  6. A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study sites
    Smilow Cancer Hospital - Yale New Haven Health · Smilow Cancer Hospital Phase 1 Unit · Yale - New Haven Hospital - Yale Cancer Center
    Registry record
    NCT07090499 · updated
  7. Phase 1 Study of PF-08046033 in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study sites
    Smilow Cancer Hospital - Yale New Haven Health · Smilow Cancer Hospital Phase 1 Unit · Yale - New Haven Hospital - Yale Cancer Center
    Registry record
    NCT07519655 · updated
  8. A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BlossomHill Therapeutics
    Study site
    Yale University - Cancer Center
    Registry record
    NCT06706076 · updated
  9. M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    EMD Serono Research & Development Institute, Inc.
    Study site
    Yale Cancer Center
    Registry record
    NCT07166601 · updated
  10. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Synthekine
    Study site
    Yale New Haven Hospital, Yale Cancer Center
    Registry record
    NCT05098132 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in New Haven, CT on ClinicalTrials.gov.

Prostate cancer studies recruiting in New Haven

  1. A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

    • Phase 1/2
    • Ages 18 and older
    • Male participants
    Sponsor
    Genentech, Inc.
    Study site
    Yale Cancer Center
    Registry record
    NCT07567846 · updated
  2. A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    Yale University Hospital
    Registry record
    NCT03972657 · updated
  3. A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Genentech, Inc.
    Study site
    Yale Cancer Center
    Registry record
    NCT05800665 · updated
  4. Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

    • Phase 1/2
    • Ages 18 and older
    • Male participants
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Yale University
    Registry record
    NCT06800313 · updated
  5. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    • Phase 1
    • Ages 18 to 100
    • Male participants
    Sponsor
    Janux Therapeutics
    Study site
    Yale New Haven Hospital
    Registry record
    NCT05519449 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in New Haven, CT on ClinicalTrials.gov.

Lymphoma studies recruiting in New Haven

  1. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study site
    Yale University
    Registry record
    NCT04726241 · updated
  2. Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Yale University
    Registry record
    NCT05272384 · updated
  3. A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Yale University School of Medicine - Yale Cancer Center
    Registry record
    NCT07101328 · updated
  4. Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

    • Phase 1/2
    • From 6 months, up to 25 years
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Yale New Haven Hospital ( Site 1012)
    Registry record
    NCT06395103 · updated
  5. Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Yale University
    Registry record
    NCT06860594 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in New Haven, CT on ClinicalTrials.gov.

Ask about studies near New Haven

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-9038

or send a short form

How should we reach you?

Call